Summary: Centessa Pharmaceuticals announced positive interim data from its ongoing phase 1 trial of ORX750, an orexin receptor 2 agonist, in acutely sleep-deprived healthy volunteers. The trial demonstrated that ORX750 significantly increased wakefulness, with the 2.5 mg dose … [Read more...]